Current Report Filing (8-k)
July 21 2017 - 9:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest
event reported): July 21, 2017
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number,
including area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
On July 21, 2017, Nektar Therapeutics,
a Delaware corporation (“Nektar”), was informed by the European Medicines Agency’s Committee for Medicinal Products
for Human Use (the “CHMP”) that it has adopted a negative opinion for the conditional marketing authorization application
for ONZEALD
TM
in the European Union (the “MAA”). Nektar intends to appeal the CHMP opinion and immediately
seek a re-examination of the opinion by the CHMP. Nektar and Daiichi Sankyo Europe GmbH will continue to collaborate on ONZEALD
TM
during the re-examination process.
SIGNATURES
Pursuant to the requirement of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
By:
|
/s/ Mark A. Wilson
|
|
|
|
Mark A. Wilson
|
|
|
|
General Counsel and Secretary
|
|
|
|
|
|
Date: July 21, 2017
|
|
|
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024